Non-Animal Models (NAMs) in Practice: Approaches for Preclinical Safety and Efficacy Screening

Este webinar abordará

UK, US, and EU perspectives on New Approach Methodologies.

Case studies spanning:

Whole blood bioassays.
Isolated primary immune cell assays.
Our ex vivo skin explant platform.
Reconstructed skin models for efficacy and tolerance tests.
Applications of precision cut lung slices for respiratory research without animal testing.

Inscreva-se para se registrar

Data: 2026-10-15

Tempo: 11:00 AM (EDT)

Idioma : English

Tarifa: Free

Tópicos: Lab Testing

Palestrantes: Kelsey Retting, Arnaud Huard, Callum O Kane

Registrar

O que você aprenderá

Join us on October 15, 2026 (1700 CEST / 1500 UTC) for our live webinar: Non-Animal Models in Practice: Approaches for Preclinical Safety and Efficacy Screening.

In this webinar, we’ll cover:

The history and status of NAMs in EU, UK, and US preclinical testing.
Ex vivo platform data from human blood bioassays.
Dermal safety and efficacy testing without animal models.
Respiratory indication testing using human-relevant alternatives.

Equip your team with a clearer view of where non-animal approaches really stand today, and where they may head next.

Sobre os palestrantes

Kelsey Retting

Senior BD Manager, QIMA Life Sciences

Kelsey is a Senior Business Development Manager at QIMA Life Sciences with a PhD in Biological Chemistry from UCLA and a career spanning drug discovery, in vitro pharmacology, and translational research. She has worked across large pharmaceutical companies, biotechnology firms, and start-ups, developing assays and complex 3D tissue-engineered and bioprinted models for disease modeling, compound screening, and preclinical development.

Arnaud Huard

Study Director, QIMA Bioalternatives

Arnaud is a study directeur at QIMA Bioalternatives, specialised in immuno-inflammation research. He achieved a PhD on resolution of inflammation in Frankfurt, followed by two postdocs in Geneva, working on skin inflammation, psoriasis and inflammasome biology, in the context of hyperinflammatory syndrome.

Callum O Kane

Market Segment Lead, QIMA Life Sciences

Callum began his research career at Queen's University Belfast, gaining a PhD in pathogen epigenetics, before joining the Axis Bio science team. He spent five years with Axis, leading cell culture projects and R&D, and acting as study director for in vivo and in vitro research projects, before joining QIMA Life Sciences.

Leitura adicional

Sobre a organização

A QIMA, líder global em serviços de garantia de qualidade e soluções de conformidade, ajuda empresas a oferecer produtos em que os consumidores podem confiar por meio de inspeção, testes, auditoria e certificação. Combinando expertise humana em campo com tecnologia inteligente, a QIMA apoia mais de 30.000 empresas nos setores de Bens de Consumo, Alimentos e Agroindústria, Cosméticos e Cuidados Pessoais, além de Farmacêutico e Biotecnologia, presente em mais de 100 países.

Webinars relacionados

Ver tudo